What are the potential interactions between mirtazapine (Remeron) and lamotrigine (Lamictal)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mirtazapine and Lamotrigine Interactions

There are no clinically significant pharmacokinetic or pharmacodynamic interactions between mirtazapine and lamotrigine, and these medications can be safely co-prescribed.

Mechanism and Interaction Profile

Mirtazapine Pharmacology

  • Mirtazapine enhances noradrenergic and serotonergic neurotransmission through α2-adrenergic receptor blockade, with additional antagonism at 5-HT2, 5-HT3, and H1 receptors 1, 2
  • The drug is extensively metabolized by hepatic cytochrome P450 enzymes, but in vitro data indicate mirtazapine is unlikely to inhibit metabolism of drugs processed by CYP1A2, CYP2D6, or CYP3A4 3
  • Elimination half-life of 20-40 hours allows once-daily dosing 1, 3

Lamotrigine Considerations

  • The critical interaction concern with lamotrigine involves combined oral contraceptives (COCs), not mirtazapine 4
  • COCs significantly decrease lamotrigine levels and may increase seizure activity, warranting a Category 3 classification when used together 4
  • Lamotrigine does not have documented interactions with antidepressants through cytochrome P450 pathways 4

Clinical Safety Profile

No Evidence of Interaction

  • Neither medication appears in drug interaction warnings for the other in guideline literature 4
  • Mirtazapine's metabolic profile suggests minimal potential for clinically significant drug-drug interactions 3, 5
  • Both medications can be used in combination for patients requiring mood stabilization and antidepressant therapy

Complementary Therapeutic Benefits

  • Mirtazapine may be particularly useful when combined with lamotrigine in patients with depression, anxiety, insomnia, and poor appetite 4
  • The sedating and appetite-stimulating properties of mirtazapine (15-45 mg at bedtime) can address common comorbid symptoms 4
  • Mirtazapine demonstrates early onset of antidepressant action within 1-2 weeks, with sleep and anxiety improvements potentially occurring within the first week 3, 5

Practical Prescribing Guidance

Dosing Recommendations

  • Start mirtazapine at 7.5-15 mg at bedtime, with therapeutic range of 15-45 mg daily 4, 1
  • Lamotrigine dosing should follow standard titration protocols for the specific indication (epilepsy or bipolar disorder) 4
  • No dose adjustments are required for either medication when used together

Monitoring Parameters

  • Monitor for mirtazapine's common adverse effects: sedation, increased appetite, weight gain, and dizziness 1, 2, 6
  • Weight gain from mirtazapine could theoretically worsen obstructive sleep apnea if present 4
  • Continue standard lamotrigine monitoring including assessment for rash and seizure control 4

Special Populations

  • In patients with hepatic or renal impairment, mirtazapine clearance may be reduced, requiring careful dose titration 3, 5
  • Both medications require dose adjustments in hepatic/renal dysfunction, but this does not create additional interaction concerns 3

Common Pitfalls to Avoid

  • Do not confuse lamotrigine's significant interaction with oral contraceptives with other drug combinations 4
  • Avoid attributing sedation solely to drug interaction; mirtazapine's H1 antagonism causes dose-dependent sedation independent of other medications 1, 2
  • Do not discontinue mirtazapine abruptly, though it has lower discontinuation syndrome risk than SSRIs 4

References

Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Mirtazapine, an antidepressant.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.